Piperidine derivatives having anxiolytic effect

Abstract: Piperidine compounds having the general general Formula I wherein R 1 is a group having the general Formula II : wherein X is CHR 10 , O, S, SO, SO 2 or NR 10 , R 10 being hydrogen, alkyl or alkenyl, an amino group, sulfonyl, optionally substituted phenyl or a hetero aromatic group; Y is CH, CH 2 , NH, C=O or C=S; R a ― R d are substituents; U is CH 2 , O or S; Q 1 is a bond , alkylene or alkenylen and Q 2 alkylene having at least two C-atoms or alkenylene R 2 and R 3 are hydrogen, or alkyl or they may together form an ethylene or propylene bridge; R 4 to R 7 are substituents; and Z 1 is substituent, Z 2 is hydrogen and Z 3 is (CH 2 ) n wherein n is 0; show potent sigma receptor activity. Furthermore they show effect in animal models indicative of anxiolytic properties. Accordingly they are useful as medicines for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile dementia of the Alzheimer type or Parkinson ' s disease.

Description: The present invention relates to a class of piperidine compounds having anxiolytic effect and potently binding to the sigma receptors and therefore being useful in the treatment of psychic and neurologic disorders. Various related compounds are known from the prior art. So, US patents Nos. 3,686,186 and 3,745,165 disclose spiro[phthalan-1,4'-piperidine] and spiro[isochroman-3,4'-piperidine] compounds optionally having a benzyl substituent at the piperidine N-atom. The phthalan compounds are said to be useful as antidepressants as indicated by their ability to reverse reserpine hypothermia, whereas the isochromane compounds are stated to be useful as hypotriglyceridemics. German Offenlegungsschrift No. 2,458,176 and the corresponding US patent No. 3,985,889 generically describe inter alia 1,3-dihydrospiro[isobenzofuran-1,4'-piperidine] or 1,3-dihydrospiro[isobenzofuran-1,3'-pyrrolidine] compounds substituted at the ring N-atom with lower alkyl, cycloalkyl or phenyl(C 2-4 )alkyl and optionally having an oxo group attached to the furan ring. The compounds are alleged to be useful as tranquilizers as demonstrated by their ability to display effects on behaviour and reflex depression and on muscle relaxation, and they are claimed also to be useful in the treatment of pain as demonstrated in the 2-phenyl-1,4-quinone induced writhing assay in mice. However, only pharmacological data for one such compound without an oxo substituent in the furan ring, i.e. the compound 1,3-dihydro-1'-methyl-spiro[isobenzofuran-1,4'-piperidine], are presented, and only four such compounds having a substituent different from methyl on the piperidine N-atom are specifically disclosed, i.e. 1'-cyclopropylmethyl-, 1'-[3-(4-fluoro-benzoyl)propyl]-, 1'-[4,4-bis(4-fluorophenyl)butyl]- and 1'-acetyl-1,3-dihydrospiro[iso-benzofuran-1,4'-piperidine] . No indication of effect on sigma-receptors is given. Japanese patent publication JP Kokai 55 143,980 generically describes inter alia a very broad class of spiro[chromane-piperidine] compounds which are optionally substituted at the piperidine N-atom with an alkyl, cycloalkyl, allyl, aryl, aralkyl, or arylcycloalkyl group and optionally substituted in the chromane ring with an oxo group. However, with respect to such spirochromane compounds having no oxo substituent in the chromane ring only compounds having a methyl, phenyl or benzyl group at the piperidine N-atom are specifically disclosed. These compounds are claimed to possess antiallergic activity and no suggestion of activity in the central nervous system is given. European patent publication No EP 0 414 289 A1 generically describes a class of 1,2,3,4-tetrahydro-spiro[naphthalene-1,4'-piperidine] and 1,4-dihydro-spiro[naphthalene-1,4'-piperidine] derivatives substituted at the piperidine N-atom with a "hydrocarbon" and aleged to have selective sigma receptor antagonistic activity. The term "hydrocarbon" as defined in said patent covers all possible straight chained, cyclic, heterocyclic etc. groups; however, only compounds having benzyl, phenethyl, cycloalkylmethyl, furyl- or thienylmethyl or lower alkyl or alkenyl as the "hydrocarbon" substituent at the piperidine nitrogen atom being specifically disclosed. The compounds are stated to displace tritiated di-tolyl guanidine (DTG) from sigma sites with potencies better than 200 nM. As a particularly preferred compound is mentioned 1'-benzyl-1,2,3,4-tetrahydro-spiro[naphthalene-1,4'-piperidine]. European patent publication No EP 0 445 974 A2 generically describes the corresponding spiro[indane-1,4'-piperidine] and spiro[benzocycloheptene-5,4'-piperidine] derivatives. Again the compounds are only stated to displace tritiated di-tolyl guanidine (DTG) from sigma sites with potencies better than 200 nM EP Application No. EP-A2-0 431 943 relates to a further extremely broad class of spiropiperidine compounds substituted at the piperidine N-atom. Said compounds are alleged to be useful as antiarrhythmics and for impaired cardiac pump function. Said application exemplifies several compounds, the majority of which contain an oxo and/or a sulfonylamino substituent in the spiro cyclic ring system. Of the remainder compounds, the main part has another polar substituent, such as nitro, amino, a fused imidazo group etc. attached to the spiro nucleus and/or they have some polar substituents, such as sulfonylamino, nitro, amino, etc. in the substituent on the piperidine N-atom. Furthermore some of the compounds have heteroaryl alkyl substituents on the piperidine N-atom, whereas only a very few of those compounds exemplified do not have such substituents, i.e. a couple of 6-methoxyspiro[2 H -1-benzopyran-2,4'-piperidines] having a phenylsubstituent on the piperidine N-atom and a few spiro[3 H -1-benzopyran-3,4'-piperidine]'s having a benzyl, phenethyl, hexyl or heptyl substituent on the piperidine N-atom. No suggestion or indication of effect of the compounds on the sigma receptors is given. US patent No. 4,420,485 discloses 1'-[3-(6-fluoro-1,2-benzoisoxazol-3-yl)propyl]-spiro[benzofuran-2(H),4'-piperidines] optionally having one or two substituents in the benzofuran ring. The compounds are claimed to be useful as antihypertensives. No mention or suggestion of effects in the treatment of psychic or neurological disorders is given. German Offenlegungsschrift No 28 27 874 corresponding to U.S. Patent No. 4,251,538 generically discloses a class of 3-[4-(4-phenyl-piperidin-1-yl)-butyl]- or 3-[4-(4-phenyl-tetrahydropyridyl-1-yl)-butyl]indole derivatives optionally substituted in the indole, piperidinyl or tetrahydropyridyl and/or phenyl groups. The compounds are said to show dopamine agonist effects and serotonin reuptake inhibiting effects in the central nervous system, and accordingly to be useful in the treatment of Parkinson's disease and depression. However, no documentation for such effects is given in the specification, no pharmacological data at all being given, and certainly no indication or suggestion of effect on the sigma receptor is given. Furthermore, the majority of the compounds listed in the specification, of which obviously only a few have actually been prepared, are tetrahydropyridyl compounds and/or they have an oxo substituent in the butyl chain. Only a few piperidyl compounds without an oxo substituent in the butyl chain are mentioned, i.e. 3-[4-(4-phenyl-1-piperidyl)-butyl]-indole and the 1-methyl-, 1-phenyl- and 2-methyl-derivatives thereof as well as derivatives thereof substituted with halogen, methyl or trifluoromethyl in the 4-phenyl substituent on the piperidyl group thereof. With respect to physical data only melting point for one such compounds is given. International Patent Application No WO 91/09594 published on July 11, 1991 relates i.a. to sigma receptor ligands being 4-phenyl-piperidine compounds and having an optionally substituted "heteroaryl"-alkyl, -alkenyl, -alkynyl, -alkoxy or -alkoxy-alkyl substituent on the piperidine N-atom. The term "heteroaryl"-alkyl is defined by mention of a very broad class of such substituents. However only four N-substituted 4-phenyl-piperidine compounds are specifically disclosed which are all 1-(phenyl-lower alkyl)-4-phenyl-piperidines and only four compounds having a "heteroaryl"-alkyl substituent are specifically mentioned, which are all piperazine (and not piperidine) compounds.The compounds are stated to be antipsychotics. From studies of the biology and function of sigma receptors, evidence has been presented that sigma receptor ligands may be useful in the treatment of psychosis and movement disorders, such as dystonia and tardive dyskinesia, and motor disturbances associated with Huntington's chorea or Tourette's syndrome and in Parkinson's disease (Walker, J. M. et al, Pharmacological Reviews, 1990, 42, 355). The known sigma receptor ligand rimcazole clinically shows effects in the treatment of psychosis (Snyder, S.H., Largent, B.L. J. Neuropsychiatry 1989 , 1, 7) and a group of sigma receptor ligands have been descibed to show antihallucinogenic activity in animal models (International Patent Publication No WO 9103243). Furthermore, sigma receptor ligands have been reported to be involved in modulation of NMDA receptor mediated events in the brain and to act as anti-ischemic agents in in vivo tests (Rao, T. S. et al , Molecular Pharmacology, 1990 , 37 , 978). In addition to ischemia they may also be useful in the treatment of other such NMDA receptor mediated events, e.g. epilepsy and convulsion. Also, some sigma receptor ligands have been found to show anti-amnesic effects in an animal model (Early et al., Brain Research 1991, 546 , 281-286). Sigma ligands have been shown to influence central acetylcholine levels in animal models (Matsuno et al, Brain Research 1992, 575 , 315-319; Junien et al, Eur. J. Pharm. 1991, 200, 343-345) and may, therefore, have potential in the treatment of senile dementia of the Alzheimer type. Finally, some guanidine derivatives having sigma receptor activity have been disclosed to be useful as anxiolytics (International Patent Publication No. WO 9014067). Accordingly, agents potently acting on the sigma receptors in the central nervous system are believed to be of potential use in the therapy of such conditions. It has now been found that a certain class of piperidine compounds bind at sigma receptors with potencies which generally are 2-3 orders of magnitude higher than the potency limit indicated in European patent publication EP 0 414 289 A1. Furthermore the compounds of said class have been found to show anxiolytic effects in animal models. Said class of compounds consists of compounds having the general Formula I wherein R 1 is b) a group having the general Formula II : wherein X is CHR 10 , O, S, SO, SO 2 or NR 10 , R 10 being hydrogen, lower alkyl or alkenyl, cycloalkyl or cycloalkylalkyl, cycloalkenyl or cycloalkenylalkyl, acyl, aminoalkyl, mono- or dialkylaminoalkyl, sulfonyl or arylalkyl or phenyl optionally substituted with one or more substituents independently selected from the following: halogen, lower alkyl, lower alkoxy, hydroxy, trifluoromethyl, and cyano, or R 10 is 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-thiazolyl, 2-oxazolyl, 2-imidazolyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl; one or two of the dotted lines may be a bond; when the dotted line emanating from Y indicates a bond, Y is N or CH; or when said dotted line indicates no bond, Y is CH 2 , NH, C=O or C=S; R a - R d are independently selected from hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, lower alkylthio, lower alkylsulphonyl, lower alkyl- or dialkylamino, cyano, trifluoromethyl, or trifluoromethylthio; U is CH 2 , O or S; or when, one of the dotted lines emanating from U indicates a bond, U is CH; Q 1 is a bond, and Q 2 is alkylene having at least two C-atoms, or alkenylene Q 2 having together from 2 to 20 carbon atoms; and R 2 and R 3 are independently hydrogen, lower alkyl or they may be linked together thereby forming an ethylene or propylene bridge; R 4 to R 7 are independently selected from hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy, lower alkylthio, lower alkyl- or dialkylamino, cyano, trifluoromethyl, or trifluoromethylthio; and Z 1 is a group as defined for R 4 - R 7 , Z 2 is hydrogen and Z 3 is (CH 2 ) n wherein n is 0; and acid addition salts or prodrugs thereof. Accordingly the present invention provides the use of piperidine compounds having the above defined general Formula I or acid addition salts or prodrugs thereof for the manufacture of a pharmaceutical preparation for the treatment of anxiety, psychosis, epilepsy, convulsion, movement disorders, motor disturbances, amnesia, cerebrovascular diseases, senile dementia of the Alzheimer type or Parkinson's disease. Some of the compounds of the general Formula I may exist as optical isomers thereof; and such optical isomers are also embraced by the invention. The term alkyl is intended to mean a C 1 -C 20 straight chain or branched alkyl group and similarly alkenyl means a C 2 -C 20 straight chain or branched alkenyl group having one or more unsaturated bonds in the chain. The term cycloalkyl designates a carbocyclic ring having 3-8 carbon atoms inclusive or a bicyclic or tricyclic carbocycle, such as adamantyl. The terms lower alkyl, lower alkoxy, lower alkylthio, etc. designate such branched or unbranched groups having from one to six carbon atoms inclusive. Exemplary of such groups are methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1-propyl, methoxy, ethoxy,1-propoxy, 2-propoxy, methylthio, ethylthio, 1-propylthio, 2-propylthio, methylsulphonyl, ethylsulphonyl, or the like. Halogen means fluoro, chloro, bromo or iodo. The term "sulfonyl" is used in the meaning alkyl or aryl substituted sulfonyl, and similarly "acyl" is used in the meaning alkyl- or arylcarbonyl The term "one or two of the dotted lines may be a bond" is intended to mean that each of the dotted lines may or may not represent a bond, i.e. that the ring and the side chain respectively may or may not have a double bond in the positions of the dotted lines in Formula II , provided that only two at a time indicate a bond and that adjacent dotted lines do not both indicate a bond. The acid addition salts of the invention are pharmaceutically acceptable salts of the compounds of Formula I formed with non-toxic acids. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, embonic, succinic, oxalic, bis-methylenesalicylic, methanesulfonic, ethanedisulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acids, as well as the 8-halotheophyllines, for example 8-bromo-theophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. The movement disorders and motor disturbances which may be treated by the preparation according to the invention are e.g. dystonia and tardive dyskinesia and motor disturbances associated with Huntington's chorea or Tourette's syndrome. Dystonia may be acute or tardive and may be caused by neuroleptics or have another reason. Cerebrovascular diseases are such disorders caused by cerebral infarction, cerebral hemorrhage, cerebral arteriosclerosis, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism, or the like, e.g. ischemia, hypoxia, anoxia. The compounds of the invention have been found to displace tritiated di-tolyl guanidine (DTG) from sigma sites in vitro with potencies better than about 40 nM, and the great majority better than 1 nM, i.e. they are binding at the sigma receptors much more potently than sigma receptor ligands such as e.g. BMY 14802 and rimcazole. Furthermore, most of the present compounds have proven to be very selective ligands on the sigma receptors. For example as compared to the α 1 adrenoceptors and dopamine D 2 receptors, the main part of the present compounds have been found to show ratios of binding affinities (IC 50 alpha/sigma and dopamine/sigma, respectively) of 30-10000. Furthermore, the compounds have proven to show very potent anxiolytic effects in an animal behaviour test in extremely low doses i.e. with EC 50 values in the ng - µg/kg range. Particularly preffered compounds are: 1 -(4-Fluorophenyl)-3-[4-(4-(4-fluorophenyl)-1-piperidyl)-1-butyl]indole; 4-Fluorophenyl-3-[4-(4-(4-fluorophenyl)-1-piperidinyl)-1-butyl]-5-trifluoromethylindazol; Some of the compounds used in accordance with the invention are novel, and accordingly in another aspect the present invention relates to novel piperidine derivatives having the general Formula I as defined above with the proviso that if X is NR -10 , where R 10 is hydrogen, alkyl or unsubstituted phenyl Y is CH and the dotted line emanating from Y indicates a bond, then -U-Q 2 - may not be alkyl having less than 5 carbon atoms; The present invention also provides a pharmaceutical composition comprising at least one novel piperidine compound according to the invention as defined above or a pharmaceutically acceptable acid addition salt thereof or prodrug therefore in combination with one or more pharmaceutically acceptable carriers or diluents. The pharmaceutical compositions of this invention or those which are manufactured in accordance with this invention may be administered by any suitable route, for example orally in the form of tablets, capsules, powders, syrups, etc., or parenterally in the form of solutions for injection. For preparing such compositions methods well known in the art may be used, and any pharmaceutically acceptable carriers, diluents, exipients, or other additive usually used in in the art may be used. Conveniently, the compounds of the invention are administered in unit dosage form containing said compound in an amount of about 0.01 to 50 mg. The total daily dose usually ranges of about 0.05 - 100 mg, and most preferably about 0.1 to 20 mg of the active compound of the invention. The compounds of Formula I may be prepared by: a) reducing the amide carbonyl of a compound of Formula III wherein R 2 - R 7 and Z 1 - Z 3 are as previously defined and R 11 is such a group that CH 2 -R 11 is a group comprised by the definition of R 1 ; b) alkylating a compound of Formula IV wherein R 2 - R 7 and Z 1 - Z 3 are as previously defined, with an alkylating reagent of the formula R 1 -V wherein R 1 is as previously defined and V is a suitable leaving group such as halogen, mesylate or tosylate; c) reductive alkylation of amines of Formula IV with aldehydes of the formula R 11 -CHO or carboxylic acids of the formula R 11 -COOH or ketones of the formula R 12 -CO-R 13 wherein R 2 -R 7 , R 11 , and Z 1 -Z 3 are as previously defined and R 12 and R 13 are such groups that R 12 -CH-R 13 is a group comprised by the definition of R 1 ; d) reducing the C=Y 1 double bond in a compound of Formula V wherein R a -R d , X, U, Q 1 , Q 2 , R 2 -R 7 , and Z 1 -Z 3 are as previously defined and Y 1 is CH or N; e) oxidizing a compound of Formula VI to an oxo compound of Formula VII: wherein R a -R d , X, U, Q 1 , Q 2 , R 2 -R 7 , and Z 1 -Z 3 are as previously defined; f) alkylating a compound of Formula VIII for obtaining a compound of general Formula I wherein X = NR 10' , R 10' being lower alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl or cycloalkenylalkyl, wherein R a -R d , Y, U, Q 1 , Q 2 , R 2 -R 7 , and Z 1 -Z 3 are as previously defined, with an alkylating reagent of the formula R 10' -V 1 , wherein R 10' is as previously defined and V 1 is a suitable leaving group, e.g. halogen, mesylate, or tosylate; or acylating a compound of the Formula VIII with an acylating reagent having the formula R 10" -CO-Hal, wherein Hal is halogen and R 10" is a group which together with CH 2 form the group R 10' , and subsequently reducing the acylated compound of Formula VIII ; g) arylating a compound of Formula VIII for obtaining a compound of general Formula I wherein X = NR 10''' , R 10''' being optionally substituted phenyl or heteroaryl, with an arylating agent of the formula Ar-V 1 wherein Ar is optionally substituted phenyl or heteroaryl and V 1 is as previously defined; h) for obtaining a compound of general Formula I wherein X = N-CO-R 10' or N-CO-Ar, wherein R 10' and Ar are as previously defined, acylating a compound of Formula VIII with an acylating agent of the formula R 10' -CO-Hal or Ar-CO-Hal, wherein Hal is as previously defined; i) for obtaining a compound of general Formula I wherein X = N-SO 2 -R 10' or N-SO 2 -Ar, wherein R 10' and Ar are as previously defined, sulfonylating a compound of Formula VIII with a sulfonylating agent of the formula R 10' -SO 2 -Hal or Ar-SO 2 -Hal, wherein Hal is as previously defined; j) reductive alkylation of compounds of Formula VIII with carbonyl compounds of formula R 14 -CO-R 15 wherein R 14 and R 15 are such groups that R 14 -CH-R 15 is a group R 10 as previously defined; k) making a ring closure reaction of the hydrazone IX to the indazole derivative X wherein R a -R d , U, Q 1 , Q 2 , R 2 -R 7 , R 10 , and Z 1 -Z 3 are as previously defined and Hal is halogen; I) reducing the quarternized pyridine derivative of Formula XI in which R 1 -R 7 , Z 1 and V 1 are as previously defined; whereupon the compound of Formula I is isolated as the free base or a pharmaceutically acceptable acid addition salt thereof. The reduction according to method a) may preferably be carried out in an inert organic solvent such as diethyl ether or tetrahydrofuran in the presence of lithium aluminium hydride at reflux temperature. The amides of Formula III are conveniently prepared by treating piperidine derivatives of Formula IV with suitable carboxylic acid chlorides of formula R 11 -COCl in the presence of base (potassium carbonate or triethylamine). When R 11 -CH 2 designates a group of Formula II the corresponding carboxylic acid chlorides of Formula XII, wherein R a -R d , X, Y, U, and Q 1 are as previously defined and Q 2' is such a group that Q 2' -CH 2 is a group Q 2 as previously defined, are prepared from the corresponding carboxylic acids by known methods. The piperidine derivatives of Formula IV where Z 1 and Z 2 are not linked are prepared by known methods, see e.g. US Pat. No. 2,891,066; McElvain et al J. Amer. Chem. Soc. 1950, 72 , 3134; Bally et al Chem.Ber. 1887, 20, 2590. Alkylation of a compound of Formula IV according to method b) is conveniently performed in an inert organic solvent such as a suitably boiling alcohol or ketone, preferably in the presence of a base (potassium carbonate or triethyl amine) at reflux temperature. The preparations of alkylating reagents of formula R 1 -V where R 1 designates a group having the general Formula II are illustrated by examples in the following reaction schemes. In the formulas of the reaction schemes R a -R d , V and Ar are as previously defined, and E designates a 1-piperidyl group of general Formula IV. Indenes of Formula II are conveniently prepared according to Scheme 1, in which R a - R d and V are as previously defined. Method 1 is a conventional Reformatsky condensation performed with activated zinc. Method 2 consists of a lithium aluminium hydride reduction performed in an inert organic solvent such as diethyl ether or tetrahydrofuran at reflux temperature. The elimination in Method 3 is preferably performed in a suitable alcohol, e.g. methanol, in the presence of a strong mineral acid, e.g. concentrated hydrochloric acid. Preferably, Method 4 is treatment with methanesulfonyl chloride in the presence of triethyl amine in dichloromethane, thus giving the corresponding methanesulfonate, but may alternatively be conversion of the hydroxy group to a halogen by means of a suitable reagent, e.g. thionyl choride. Indanes of Formula II are prepared according to Scheme 2, in which R a - R d and V are as previously defined. Method 1a is analogous to Method 1 with the modification that elimination of water is performed directly on the crude product by means of concentrated hydrochloric acid. The mixture of isomers obtained is reduced according to Method 2. One of the isomers obtained is isolated while the remaining mixture is hydrogenated in a conventional Parr apparatus (Method 5) in the presence of a suitable noble metal catalyst, e.g. palladium or platinum. Indoles of Formula II are most conveniently prepared either from indole alkanoic acid, exemplified by indole butanoic acid as described in Eur. Pat. Appl. No. 376607, or according to Scheme 3, in which R a - R d , Ar and V are as previously defined. The starting indoxyl ester is prepared by the method described in US Pat. No. 4,710,500 and references therein. The alkylation in Method 5 is performed in an inert, suitably boiling, organic solvent, e.g. an alcohol or a ketone, preferably in the presence of a base (potassium carbonate or triethyl amine). The decarboxylation in Method 6 is preferably performed thermally, after hydrolysis of the diester to the diacid, in a suitable inert solvent, e.g. quinoline, dimethyl formamide, or N -methyl-2-pyrrolidinone (NMP) in the presence of copper. Indol-3-yloxypropyl derivatives can also be obtained by heating a mixture of 3-acetoxyindoles and 1,3-propylene glycol in the presence of sulfuric acid, thereby obtaining 3-(indol-3-yloxy)-1-propanol derivatives which are converted to the corresponding methanesulfonates or halides by Method 4. Benzofuranes and 2,3-dihydrobenzofuranes of Formula II are prepared according to Schemes 4 and 5, in which R a - R d and E are as previously defined. Method 7 is a conventional conversion to the methyl ester by treating the carboxylic acid with thionyl chloride followed by addition of methanol to the intermediate carboxylic acid chloride. The 2,3-dihydrobenzofuranes are obtained by reduction with magnesium (Method 8) at this stage, while the benzofuranes are obtained by skipping this step. Method 9 consists of conversion of the alcohol group to the corresponding chloride by means of thionyl chloride followed by treatment with dimethyl malonate in a suitable solvent, e.g. NMP, in the presence of base, preferably potassium tert-butoxide. Method 11 is similar to Method 6 except the decarboxylation is performed without addition of copper. Method 12 consists of a conventional conversion of the carboxylic acid to the amide via the carboxylic acid chloride. Prolongation of the side chain is accomplished by conversion of the hydroxy group to the chloride by treatment with preferably thionyl chloride in dichloromethane in the presence of a few drops of dimethyl formamide (Method 13) followed by treatment with a cyanide salt, e.g. potassium cyanide, in a suitable aprotic dipolar solvent, preferably dimethyl sulfoxide, at 100 - 200 °C (Method 14). Hydrolysis of the cyano group is accomplished with mineral acid at elevated temperature (Method 15). Benzo[b]thiophenes and 2,3-dihydrobenzo[b]thiophenes of Formula II are prepared by methods analogous to the methods described in Schemes 4 and 5. Benzo[b]thiophen-3-ylmethyloxyethyl derivatives are prepared from methyl benzo[b]thiophene-3-carboxylate by reduction to the methanol derivative with lithium aluminium hydride followed by alkylation with ethyl bromoacetate and subsequent reduction to benzo[b]thiophen-3-ylmethyloxyethanol derivatives which are converted to the target compounds via Method 4. Benzofuran-3-ylmethyloxyethyl derivatives are prepared analogously. Benzo[b]thiophene-S,S-dioxide derivatives are obtained by oxidation of the corresponding benzo[b]thiophene derivatives according to standard literature methods. 2,3-Dihydroindoles of Formula II are prepared by methods analogous to method d). Indolones of Formula II are prepared by methods analogous to method e). Indazoles of Formula II are prepared by methods analogous to method j). Reductive alkylation of amines of Formula IV according to method c) is performed by standard literature procedures. The aldehydes , carboxylic acids, and ketones of formulas R 11 -CHO, R 11 -COOH, and R 12 -CO-R 13 , respectively, are either commercially available or are prepared according according to standard procedures or according to methods analogous to the methods described in Schemes 1-5. Reduction of the C=Y 1 double bond according to method d) is conveniently performed by catalytic hydrogenation in an alcohol with a platinum catalyst or by hydrogenation with diborane or a diborane precursor such as trimethyl amine or dimethyl sulfide complex in tetrahydrofuran or dioxane from 0 °C to reflux temperature, followed by acid catalyzed hydrolysis of the intermediate borane derivative. Alternatively, the double bond can be reduced by sodium borohydride in methanol in the presence of trifluoroacetic acid (see e.g. Berger et al J. Med. Chem. 1977, 20, 600). Oxidation of a compound of Formula VI according to method e) is performed according to Szabo-Pustay et al., Synthesis, 1979 , 276. Alkylation, acylation or sulfonylation of compounds of Formula VIII according to methods f), h) and i), respectively, are performed in an inert solvent such as a suitably boiling alcohol or ketone, preferably in the presence of a base (potassium carbonate or triethyl amine). The alkylating reagents R 10' -V 1 , the acylating reagents R 10'' -CO-V 1 , R 10' -CO-V 1 , and Ar-CO-V 1 , and the sulfonylation reagents R 10' -SO 2 -V 1 , and Ar-SO 2 -V 1 respectively, are commercially available or are prepared by standard procedures. Arylation of a compound of Formula VIII according to method g) is most conveniently performed by applying the well known Ullmann reaction. The arylating reagents Ar-V 1 are commercially available. Reductive alkylation of compounds of Formula VIII according to method j) are performed by standard literature methods. The ring closure of compounds of Formula IX according to method k) is most conveniently performed by heating a compound of Formula IX in a suitable inert organic solvent such as dimethyl formamide in the presence of a base, preferably potassium tert -butoxide. Hydrazones of Formula IX are prepared according to Scheme 6, in which R a -R d , R 10 and Hal are as previously defined. Method 16 is an addition of the Grignard reagent of 4-chloro-1-butanol to o -halobenzonitriles under standard conditions for Grignard reactions. Conversion to the hydrazone (Method 17) is accomplished by reflux in ethanol in the presence of a hydrazine. Alternatively, the hydroxy derivative resulting from Method 16 may be converted to the amine via the corresponding mesylate analogous to Method 4 and a) before conversion of the keto group. The reduction according to method I) is most conveniently performed by catalytic hydrogenation in an alcohol with a platinum catalyst. Compounds of Formulas V, VI, and VIII are prepared by methods a), b), j), k), or l). Compounds of Formula XI are prepared by treating a compound of formula R 1 -V 1 with a 4-aryl-pyridine in a suitably boiling alcohol. In the following the invention is further illustrated by examples which, however, may not be construed as limiting: EXAMPLE 2 1'-(4-Phenyl-1-butyl)spiro[isobenzofuran-1(3 H ),4'-piperidine], fumarate, 2a (preparation compound) To an ice cooled solution of 4-phenyl-1-butanol (20 g) and triethyl amine (15 g) in 200 ml of dichloromethane, a solution of methanesulfonyl chloride (12 ml) in 50 ml of dichloromethane was added dropwise. After stirring for 1 h at 10 °C the reaction mixture was washed with water. Extraction of the water phase with dichloromethane, drying of the combined organic phases over MgSO 4 followed by removal of the volatile components in vacuo, gave 29 g of a slightly yellow oil, 4-phenyl-1-butyl methanesulfonate, which was sufficiently pure for use in the next step. A mixture of spiro[isobenzofuran-1(3 H ),4'-piperidine] (2 g), 4-phenyl-1-butyl methanesulfonate (6 g) and potassium carbonate (14 g) in 75 ml of 4-methyl-2-pentanone was refluxed for 20 h. After cooling the reaction mixture was filtered and concentrated in vacuo. The remaining viscous oil was applied to a silica gel column (eluent: ether/methanol/triethyl amine = 93:5:2) giving a colorless oil which crystallized as the fumarate salt, 2a, from acetone by addition of fumaric acid. Yield: 0.7 g, mp: 197-99 °C. 3-[4-(4-Phenyl-1-piperidyl)-1-butyl)indole, 2cc , mp: 131-32 °C. 3-[4-(4-(3,4-Dichlorophenyl)-1-piperidyl)-1-butyl]indole, 2dd , mp: 118-19 °C. 5,6-Dichloro-3-[4-(4-(4-fluorophenyl)-1-piperidyl)-1-butyl]-indole, 2ee , mp: 120-21°C. 3-[6-(4-(4-Fluorophenyl)-1-piperidinyl)-1-hexyl]indole, 2ff , mp: 90-91 °C. 3-[4-(4-(2-Methoxyphenyl)-1-piperidinyl)-1-butyl]indol, oxalate, 2gg , mp: 183-88 °C. 3-[4-(4-(4-Fluorophenyl)-1-piperidyl)-1-butyl]indol-2-one, 2ii , mp: 108-10 °C. EXAMPLE 8 1'-[3-[1-(4-Fluorophenyl)-3-indolyloxy]-1-propyl]spiro[isobenzofuran-1(3 H ),4'-piperidine], oxalate, 8a. (preparation compound) A mixture of 3-acetyloxy-l-phenylindole (24 g), 1,3-dihydroxypropane (240 ml), and conc. sulfuric acid (10 ml) was heated to 80 °C for 2 h. Water was added followed by extraction with ether. The ether phase was dried over magnesium sulfate followed by removal of solvent in vacuo giving 3-(1-phenyl-3-indolyloxy)-1-propanol, sufficiently pure for use in the next step. The title compound was obtained by the method described in EXAMPLE 2 using spiro[isobenzofuran-1(3 H ),4'-piperidine] and crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield: 2 g, mp: 151-54 °C. In a similar manner was also prepared: 5-Chloro-1-(4-fluorophenyl)-3-[3-(4-(4-methylphenyl)-1-piperidinyl)-1-propyloxy]indol, 8d, mp: 111-12 °C. EXAMPLE 9 1'-[4-[1-(4-Fluorophenyl)-3-indolyl]-1-butyl]spiro[1 H -2-benzopyran-4(3 H ),4'-piperidine], maleate, 9a. (preparation compound) A tetrahydrofuran solution (500 ml) of methyl 4-(3-indolyl)-butyrate (103 g) was added dropwise to a suspension of lithium aluminium hydride (25 g) in tetrahydrofuran (1000 ml) at 40 °C followed by stirring for 1 h at room temperature. Usual work-up gave 4-(3-indolyl)-1-butanol (96 g) as an oil. Arylation with 1-fluoro-4-iodobenzene according to the method described in EXAMPLE 5 yielded 4-[1-[4-fluorophenyl)-3-indolyl]-1-butanol which was converted to the title compound 9a by the method described in EXAMPLE 2 using spiro[1 H -2-benzopyran-4(3 H ),4'-piperidine]. The maleate salt crystallized from acetone by addition of maleic acid. Yield: 1.5 g, mp: 189-90 °C. In a similar manner were also prepared: 1-(4-Fluorophenyl)-3-[4-(4-(4-fluorophenyl)-1-piperidyl)-1-butyl]indole, oxalate, 91, mp: 190-91 °C. 1-(4-Fluorophenyl)-3-[4-(4-(4-methylphenyl)-1-piperidyl)-1-butyl]indole, maleate, 9m , mp: 130-32 °C. 1-(4-Fluorophenyl)-3-[4-(4-(4-isopropylphenyl)-1-piperidyl)-1-butyl]indole, maleate, 9n, mp: 160-62 °C. 1-(4-Fluorophenyl)-3-[4-(4-(4-dimethylaminophenyl)-1-piperidyl)-1-butyl]indole, fumarate, 9o , mp: 180-82 °C. 1-Phenyl-3-[4-(4-(4-fluorophenyl)-1-piperidyl)-1-butyl]indole, oxalate, 9p, mp: 174-76 °C. 1-[4-Fluorophenyl)-3-[4-(4-(3-trifluoromethylphenyl)-1-piperidyl)-1-butyl]indole, maleate, 9t , mp: 112-13 °C. EXAMPLE 11 2,3-Dihydro-5-fluoro-3-[3-(4-(4-fluorophenyl)-1-piperidinyl)-1-propyl]benzofuran, 11a. To a suspension of 5-fluorobenzofuran-3-carboxylic acid (118 g) in 800 ml of dichloromethane, thionyl chloride (200 ml) and dimethyl formamide (1 ml) were added. After reflux for 3 h the reaction mixture was concentrated in vacuo , and the remaining oil dissolved in 800 ml of dichloromethane. Methanol (1.5 I) was slowly added and the mixture stirred for 1 h. Removal of solvents in vacuo left methyl 5-fluorobenzofuran-3-carboxylate (125 g) as an oil. The oil was dissolved in methanol (1.8 I) and magnesium turnings (7 g) was added. After the reaction had started additional magnesium (80 g) was added portionswise during 1.5 h keeping the reaction temperature at 30-40 °C. The reaction mixture was stirred for 1 h followed by addition of aq. ammonium chloride. Extraction with ether, drying the ether phase over sodium sulfate followed by removal of the solvent in vacuo , left a viscous oil, methyl 2,3-dihydro-5-fluorobenzofuran-3-carboxylate (120 g). The oil was dissolved in 500 ml of dry ether and added dropwise to a suspension of lithium aluminium hydride (32 g) in 600 ml of dry ether. The mixture was refluxed for 3 h followed by hydrolysis with water. Filtration and removal of solvent in vacuo gave 2,3-dihydro-5-fluoro-3-hydroxymethyl-benzofuran (95 g) which was converted to 155 g of 2,3-dihydro-5-fluorobenzofuran-3-ylmethyl methanesulfonate by the method described in EXAMPLE 2. Dimethyl malonate (262 g) was dissolved in NMP (2 I) and potassium tert-butoxide (202 g) was added portionwise keeping the temperature at 15-20 °C. The mixture was heated to 60 °C and a solution of 2,3-dihydro-5-fluorobenzofuran-3-ylmethyl methanesulfonate (155 g) in NMP (150 ml) was added dropwise. The mixture was stirred for 4 h at 70-75 °C followed by addition of cold water. Extraction with ether, drying the ether phase over magnesium sulfate, followed by removal of solvent in vacuo gave dimethyl 2-(2,3-dihydro-5-fluorobenzofuran-3-ylmethyl)malonate (160 g) as an oil, which was sufficiently pure for the further synthesis. The oil was dissolved in 2 l of ethanol and a mixture of 120 g of solid potassium hydroxide and 200 ml of water was added followed by reflux for 2 h. The reaction mixture was concentrated in vacuo, water was added followed by extraction with ether. The water phase was acidified with concentrated hydrochloric acid and extracted with ethyl acetate. Drying of the organic phase over magnesium sulfate and removal of solvent in vacuo gave a viscous oil which was dissolved in NMP (1 I) and kept at 150 °C for 2 h. Addition of water and extraction with ether gave, after drying over magnesium sulfate and removal of solvent in vacuo , 77 g of 3-(2,3-dihydro-5-fluorobenzofuran-3-yl)-propionic acid. Reduction with lithium aluminium hydride by the method described above yielded 51 g of 3-(2,3-dihydro-5-fluoro-benzofuran-3-yl)-1-propanol which was converted to 3-(2,3-dihydro-5-fluoro-benzofuran-3-yl)-1-propyl methanesulfonate by the method described in EXAMPLE 2. The title compound, 11a, was prepared from 3-(2,3-dihydro-5-fluoro-benzofuran-3-yl)-1-propyl methanesulfonate (4.2 g) and 4-(4-fluorophenyl)piperidine (5.5 g) by the method described in EXAMPLE 2. Yield: 1.8 g, mp: 83-85 °C. EXAMPLE 13 1'-[4-(2,3-Dihydro-3-indolyl)-1-butyl]spiro[1,3-benzodioxole-2,4'-piperidine], oxalate, 13a. (preparative compound) To a solution of 25b ( 4 g) and BH 3 -NMe 3 (10 g) in 100 ml of dioxane, conc. hydrochloric acid (12 ml) was added. After stirring for 0.5 h the mixture was refluxed for 2 h. The mixture was cooled to room temperature and 6 N hydrochloric acid (40 ml) was added followed by reflux for 1 h. The reaction mixture was made alkaline with aq. sodium hydroxide and extracted with dichloromethane. Drying of the organic phase over magnesium sulfate and removal of the solvent in vacuo gave an orange oil which was applied to a silica gel column (eluent: ethyl acetate/heptane/triethyl amine = 70:28:2). The title compound, 13a, crystallized as the oxalate salt from acetone by addition of oxalic acid. Yield: 2.3 g, mp: 182-84 °C. In a similar manner was also prepared: 2,3-Dihydro-3-[4-(4-(2-methoxyphenyl)-1-piperidinyl)-1-butyl]indol, oxalate, 13d , mp: 160-62 °C. EXAMPLE 14 1'-[2-[5-Chloro-1-(4-fluorophenyl)-3-indolyloxy]-1-ethyl]spiro[isobenzofuran-1(3 H ),4'-piperidine], oxalate, 14a. To a solution of methyl 5-chloro-1-(4-fluorophenyl)-3-indolone-2-carboxylate (50 g) and potassium carbonate (40 g) in 500 ml of acetone, ethyl bromoacetate (35 g) in 100 ml of acetone was added dropwise under reflux. After reflux for 6 h the mixture was filtered and the solvent removed in vacuo. Addition of water and extraction with ether gave, after drying over magnesium sulfate and removal of solvent in vacuo , a viscous oil, methyl 5-chloro-3-ethoxycarbonylmethoxy-1-(4-fluorophenyl)-indole-2-carboxylate, 62 g. The oil was dissolved in 800 ml of ethanol and 30 g of potassium hydroxide added. Reflux for 4 h, addition of 4 I of crushed ice followed by acidification with hydrochloric acid gave a colorless solid which was dissolved in 250 ml of NMP. Copper bronze (5 g) was added and the mixture kept at 200 °C for 4 h. Addition of water and extraction with ethyl acetate gave, after drying over magnesium sulfate and removal of solvent in vacuo , 27 g of 5-chloro-1-(4-fluorophenyl)-3-indolyloxy acetic acid. The acid was dissolved in 500 ml of tetrahydrofuran and lithium aluminium hydride (4 g) was added. After reflux for 3 h, the reaction mixture was hydrolyzed with water, filtered, and concentrated in vacuo giving 18 g of 5-chloro-1-(4-fluorophenyl)-3-(2-hydroxyethyloxy)-indole as an oil. The oil was dissolved in 250 ml of dichloromethane and triethyl amine (10 ml) was added. Methanesulfonyl chloride (10 ml) was added dropwise at 0-5 °C followed by stirring for 4 h. The reaction mixture was washed with water, dried over magnesium sulfate and concentrated in vacuo , leaving 5-chloro-1-(4-fluorophenyl)-3-indolyloxyethyl methanesulfonate (21 g) as a viscous oil. 1'-[2-[5-Chloro-1-(4-fluorophenyl)-3-indolyloxy]-1-ethyl]spiro[isobenzofuran-1(3 H ),4'-piperidine], 14a, was prepared from 5-chloro-1-(4-fluorophenyl)-3-indolyloxyethyl methanesulfonate (3 g) and spiro[isobenzofuran-1(3 H ),4'-piperidine] by the method described in EXAMPLE 2 followed by purification by column chromatography (silica gel, eluent: ethyl acetate). The title compound crystallized as the oxalate salt from acetone. Yield: 0.8 g, mp: 216-17 °C. In a similar manner was also prepared: 5-Chloro-1-(4-fluorophenyl)-3-[2-(4-(4-fluorophenyl)-1-piperidinyl)-1-ethyloxy]indol, 14b , mp: 102-5 °C. EXAMPLE 17 1'-[4-[1-(4-Fluorophenyl)-5-trifluoromethylindazol-3-yl]-1-butyl]spiro[isobenzofuran-1(3 H ),4'-piperidine], 17a. (preparation compound) To a suspension of magnesium turnings (135 g) in 300 ml of dry tetrahydrofuran, ethyl bromide (140 g) dissolved in 500 ml of dry tetrahydrofuran was slowly added followed by reflux for 20 min. A solution of 4-chloro-1-butanol (274 g) in 500 ml of tetrahydrofuran was added dropwise at reflux temperature. After stirring for 20 min, the Grignard solution was filtered and added portionwise to a solution of 2-chloro-4-trifluoromethyl-benzonitril (200 g) in 600 ml of dry tetrahydrofuran. The reaction mixture was stirred for 16 h at room temperature followed by addition af 2 N hydrochloric acid and ice. Extraction with ether, drying of the ether phase over magnesium sulfate and removal of solvent in vacuo left a viscous oil which was applied to a silica gel column (eluent: dichloromethane/ether = 3:1) giving 4-(2-chloro-5-trifluoromethylbenzoyl)-1-butanol (101 g) as an oil. The oil (80 g) was dissolved in 800 ml of ethanol and hydrazine hydrate (160 ml) was added followed by refluxing for 20 h. The reaction mixture was cooled and concentrated in vacuo. Water was added followed by extraction with ether. Drying of the ether phase over magnesium sulfate and removal of solvent in vacuo gave 79 g of the hydrazone of 4-(2-chloro-5-trifluoromethyl-benzoyl)-1-butanol as an oil. The hydrazone (20 g) was dissolved in dimethyl formamide and potassium tert-butoxide (10 g) was added. The mixture was kept at 100-120 °C for 30 min followed by addition of aq. ammonium chloride. Extraction with ethyl acetate, drying of the ethyl acetate phase over magesium sulfate, and removal of solvent in vacuo gave a viscous oil which was applied to a silica gel column (eluent: ethyl acetate) giving crystalline 4-(5-trifluoromethyl-3-indazolyl)-1-butanol)-1-butanol (2.7 g, mp: 177-79 °C). The indazole (2.7 g) was arylated with 1-fluoro-4-iodobenzene (5 g) by the method described in EXAMPLE 5 giving 4-[1-(4-fluorophenyl)-5-trifluoromethyl-3-indazolyl]-1-butanol (2.7 g, mp: 77-79 °C) which was converted to the corresponding methanesulfonate by the method described in EXAMPLE 2. The title compound, 17a , was prepared from the methanesulfonate (2 g) and spiro[iso-benzofuran-1(3 H ),4'-piperidine] (2 g) by the method described in EXAMPLE 2. Yield: 1.7 g, mp: 74-76°C. In a similar manner was also prepared: 4-Fluorophenyl-3-[4-(4-(4-fluorophenyl)-1-piperidinyl)-1-butyl]-5-trifluoromethyl-indazol, 17b, mp: 124-25 °C. EXAMPLE 19 1'-(4-(1,2-Benzisoxazol-3-yl)-1-butyl)spiro[isobenzofuran-1(3 H ),4'-piperidine], oxalate, 19a , mp: 164-65 °C. (preparation compound) A solution of 1,2-benzisoxazole-3-acetic acid (prepared according to G. Casini et al, J. Het. Chem. 6, 1969, 279) (18 g), ether saturated with dry HCI (150 ml) and methanol (200 ml) was stirred for 2 h at room temperature. Removal of the volatiles in vacuo gave methyl 1,2-benzisoxazole-3-acetate (17 g) as an oil. The oil was dissolved in tetrahydrofuran (100 ml) and added dropwise to a suspension of lithium aluminium hydride (6 g) in tetrahydrofuran (200 ml) at 0-10 °C followed by stirring for 30 min at 15 °C. Usual work-up gave 2-(1,2-benzisoxazol-3-yl)ethanol (13 g) as an oil. The ethanol derivative (13 g) was converted to the corresponding methanesulfonate by the method described in EXAMPLE 2 (yield: 20 g). A solution of the methanesulfonate (20 g) in dimethyl sulfoxide (20 ml) was added to a suspension of sodium cyanide (15 g) in dimethyl sulfoxide (40 ml) at 70 °C followed by stirring for 30 min at 70-80 °C. Water and ether was added, the phases separated and the ether phase dried over magnesium sulfate. Removal of solvent in vacuo gave 3-(1,2-benzisoxazol-3-yl)propionitrile a solid (13 g, mp: 67 °C). The nitrile was dissolved in methanol (200 ml) and HCl-saturated ether (200 ml) was added followed by stirring for 16 h at room temperature. The reaction mixture was concentrated in vacuo , water and ether added, and the phases separated. Drying of the ether phase over magnesium sulfate and removal of solvent in vacuo gave methyl 3-(1,2-benzisoxazol-3-yl)propionate (13 g) as an oil. By repeating the above mentioned steps the 3-(1,2-benzisoxazol-3-yl)propionate was converted to methyl 4-(1,2-benzisoxazol-3-yl)butyrate which was reduced with lithium aluminium hydride according to the procedure described above to 4-(1,2-benzisoxazol-3-yl)-1-butanol. By the method described in EXAMPLE 2, 4-(1,2-benzisoxazol-3-yl)-1-butyl methanesulfonate was obtained. The title compound 19a was obtained from 4-(1,2-benzisoxazol-3-yl)-1-butyl methanesulfonate (3.4 g) and spiro[isobenzofuran-1(3 H ),4'-piperidine] (2 g) by the procedure described in EXAMPLE 2. The oxalate salt crystallized from acetone by addition of oxalic acid. Yield: 2.4 g, mp: 164-65 °C. In a similar manner were also prepared: 3-[4-(4-(4-Fluorophenyl)-1-piperidyl)-1-butyl]-1,2-benzisoxazole, oxalate, 19b , mp: 174-75 °C. 3-[4-(4-(2,6-Dichlorophenyl)-1-piperidyl)-1-butyl] -1,2-benzisoxazol, fumarate, 19d , mp: 196-97 °C. EXAMPLE 21 3-[3-(4-(4-Fluorophenyl)-piperidin-1-yl)-1-propyloxy]-1,2-benzisothiazole, 21. A mixture of 4-(4-fluorophenyl)-piperidine (15 g), ethyl 3-bromopropionate (20 g), and potassium carbonate (14 g) in methyl isobutyl ketone was refluxed for 16 h. Filtration and removal of solvent in vacuo gave 26 g of crude ethyl 3-(4-(4-fluorophenyl)-1-piperidyl)propionate as an oil which was used directly in the next step. The oil was dissolved in dry tetrahydrofuran (70 ml) and added dropwise to a suspension of lithium aluminium hydride (6.5 g) in dry tetrahydrofuran (250 ml) at 15 °C under nitrogen gas. After stirring for 30 min at room temperature, water (6.5 ml), 10 N sodium hydroxide (7 ml), and water (30 ml) were added, subsequently. Filtration and removal of solvent gave 20 g of crude 3-(4-(4-fluorophenyl)-1-piperidyl)-1-propanol as an oil which was sufficiently pure for use in the next step. A solution of 3-(4-(4-fluorophenyl)-1-piperidyl)-1-propanol (10 g) in dry toluene (150 ml) was treated portionwise with a 50% xylene suspension of sodium hydride (3 g). A solution of 3-chloro-1,2-benzisothiazole (3.6 g) in dry toluene (30 ml) was added dropwise at room temperature followed by stirring for 1.5 h at room temperature. Ice was added, the phases separated and the aqeous phase extracted with ether. Drying of the combined organic phases over magnesium sulfate and removal of solvents in vacuo gave an oil which was applied to column chromatography (silica gel, eluent: ethyl acetate/heptane/triethyl amine = 50:50:4). The title compound 21 crystallized from a mixture of isopropyl ether/heptane. Yield: 1.5 g, mp: 91-92 °C. EXAMPLE 23 1-[4-Fluorophenyl)-3-[4-[3-(4-fluorophenyl)-8-azabicyclo[3,2,1]-oct-2-en-8-yl]-1-butyl]-indol, 23. A mixture of dry ether (600 ml) and 15% BuLi in hexane (500 ml) was cooled to -45 °C. A solution of 4-bromo-1-fluorobenzene (145 g) in dry ether (350 ml) was added dropwise at -45 °C followed by stirring for 1 h. A solution of 8-methyl-8-azabicyclo[3,2,1]octan-3-one (85 g) in dry ether (400 ml) was added dropwise at -50 °C followed by stirring for 30 min, the temperature raising to -20 °C. The reaction mixture was poured into 2 M hydrochloric acid and the phases separated. The ether phase was extracted with 2 M hydrochloric acid and the combined aqeous phases made alkaline with aqeous NaOH. Extraction with ethyl acetate, drying of the organic phase over magnesium sulfate and removal of solvent in vacuo, gave 3-[4-fluorophenyl)-3-hydroxy-8-methyl-8-azabicyclo[3,2,1]octane (96 g) as a solid, mp: 169 °C. The product was dissolved in trifluoroacetic acid (500 ml) followed by reflux for 1h. The reaction mixture was concentrated in vacuo, water added and the mixture made alkaline with aqeous NaOH (pH > 9). Extraction with ethyl acetate, drying of the organic phase over magnesium sulfate, and removal of solvent in vacuo gave 3-(4-fluorophenyl)-8-methyl-8-azabicyclo[3,2,1]oct-2-ene as a solid (91 g, mp: 62-63 °C). The product was dissolved in 1,1,1-trichloroethane (550 ml) and heated to 70 °C. A solution of 2,2,2-trichloroethyl chloroformate (14 ml) in 1,1,1-trichloroethane (25 ml) was added dropwise at 70 °C followed by reflux for 1 h. Additional 2,2,2-trichloroethyl chloroformate (24 ml) was added followed by reflux for 5 h. Removal of volatiles in vacuo and purification by column chromatography (silica gel, eluent: methylene chloride) gave 3-(4-fluorophenyl)-8-(2,2,2-trichloroethyloxycarbonyl)-8-azabicyclo[3,2,1]oct-2-ene (59 g) as an oil. (4-Fluorophenyl)-8-(2,2,2-trichloroethyloxycarbonyl)-8-azabicyclo[3,2,1]oct-2-ene (17 g) was dissolved in glacial acetic acid (170 ml) followed by addition of water (20 ml). The mixture was heated to 50 °C and zink dust (40 g) was added in portions. After stirring for 2 h at 50 °C the mixture was filtered and concentrated in vacuo. Water was added and the mixture made alkaline with aqeous NaOH. Extraction with ethyl acetate, drying of the organic phase over magnesium sulfate and removal of solvent in vacuo left 3-(4-fluorophenyl)-8-azabicyclo[3,2,1]oct-2-ene (7 g) as an oil. The title compound 23 was prepared from 3-(4-fluorophenyl)-8-azabicyclo[3,2,1]oct-2-ene according to the method described in EXAMPLE 9. Yield: 1.9 g, mp: 74-75°C. EXAMPLE 24 3-[4-[3-[4-Fluorophenyl)-8-azabicyclo[3.2.1]octan-8-yl]-1-butyl]-1,2-benzisoxazole, oxalate, 24, mp 169-170. A solution of 3-(4-fluorophenyl)-8-azabicyclo[3,2,1]oct-2-ene (10 g) was dissolved in glacial acetic acid (150 ml). Platinum oxide (0.5 g) was added followed by treatment with hydrogen gas at 3 atm of pressure in a conventional Parr apparatus. Filtration and removal of solvent in vacuo left a viscous oil. Water was added and the mixture made alkaline (pH > 9) with aqeous NaOH. Extraction with ethyl acetate, drying of the organic phase over magnesium sulfate and removal of solvent in vacuo gave 3-(4-fluorophenyl)-8-azabicyclo[3,2,1]-octane (9 g) as an oil. The title compound 24 was obtained from 3-(4-fluorophenyl)-8-azabicyclo[3,2,1]octane and 4-(1,2-benzisoxazol-3-yl)-1-butyl methanesulfonate (prepared as described in EXAMPLE 19) by the method described in EXAMPLE 2. The oxalate salt crystallized from acetone by addition of oxalic acid. Yield. 1.1 g, mp: 169-70 °C. PHARMACOLOGY Some of the compounds of Formula I have been tested according to an established and reliable pharmacological test as follows: INHIBITION OF 3 H-DTG BINDING TO SIGMA RECEPTORS IN RAT BRAIN IN VITRO. By this method the inhibition by drugs of the binding of 2 nM 3 H-DTG (1,3,di-o-tolyl guanidine) to sigma receptors in homogenates or membranes from rat brain without cerebellum is determined in vitro as modified from Weber et al. Proc. Natl. Acad. Sci. 1986 , 83, 8784. Tissue preparations: Homogenate: Rats (150-250 g) are decapitated and the brains (without cerebellum) quickly removed and placed on ice, weighed and homogenized in 100 vol ice-cold (0 °C) 50 mM Tris-buffer (pH 7.7) in an ethanol rinsed glass/teflon homogenizer at 0 °C and kept on ice until use. P2-membranes: Brains are homogenized in 10 vol 0.32 M sucrose in an ethanol rinsed glass/teflon homogenizer with 10 strokes up and down. The homogenate is centrifuged for 10 min at 900 x g m at 4 °C. The supernatant is decanted and centrifuged for 20 min at 50,000 g m at 4 °C. The resulting pellet is resuspended in 10 vol ice-cold 50 nM Tris-buffer (pH 7.7) and incubated for 30 min. at 37 °C. The membrane suspension is then centrifuged for further 20 min. at 50,000 g m at 4 °C. The pellet is resuspended in 50 vol. of ice-cold Tris-buffer and used immediately. Binding analysis: 0.5 ml 50 mM Tris-buffer (pH 7.7), 0.25 ml displacer (6 x 100 µM DTG, 6 x [test compound], or Tris-buffer), and 0.25 ml 6 x 2 nM 3 H-DTG are mixed into 5 ml plastic test tubes and kept at 4 °C until use. The binding reaction is initiated by mixing 0.5 ml tissue suspension into this solution and incubate at 25 °C for 20 min. Glass fiber filters (Whatman GF/B) are placed on the filter machine which is then closed tightly. Just before filtration vacuum is applied, and the filters washed with 0.1% PEI solution from a spray bottle followed by one wash with Tris-buffer. The binding reaction is stopped by filtration of the assay mixture at reduced pressure (750 mbar) followed by further 3 washes with 5 ml ice-cold Tris-buffer. The filters are then placed in counting vials and 4 ml scintillation solution added. The vials are counted in a Beckmann scintillation counter. Buffers and solutions: 50 mM Tris-buffer pH 7.7: 7.38 g Trizma - 7.7 plus distilled H 2 O ad 1 liter. 100 ml 10% polyethylenimine (PEI): 100 ml dest. H 2 O is added to approx. 20 g 50% PEI which is solubilized by stirring and heating. Diluted (1+99) before use. 6 x 2 nM 3 H-DTG: The exact volume depends on the actual concentration of the batch, but is made as close as possible to 12 nM. The containers for the radioactive solution is rinsed in 96% ethanol before use. 6 x 100 µM DTG: 14.36 mg/100 ml is kept frozen in 10 ml aliqouts. 3 H-DTG was obtained from NEN Research Products, Du Pont Denmark. Specific activity 62.3 Ci/mmol. The known sigma receptor ligands BMY 14802 and rimcazole were included in the test for comparison purposes. 3 H DTG Binding Data Compound IC50 (nM) Compound IC50 (nM) Compound IC50 (nM) 13d 2.1 14b 3.8 5f 0,04 17b 0.46 19b 0.49 19d 4.4 8d 1 1 21 0.2 23 2.5 24 1.9 2cc 1.1 2dd 1.7 2ee 1.0 9l 0.14 2ff 0.43 9m 1.6 2gg 3.3 9n 6.3 9o 6,7 2ii 5.8 9p 0.28 9t 3.2 BMY 14802 230 rimcazole 180 I is seen from Table I that the compounds used in the present invention are very potent sigma receptor ligands as compared to the reference compounds which are known in the art to be sigma receptor ligands, the potencies for the compounds tested being better than about 40 nM, and for most of the compounds tested better than about 1 nm. Furthermore, the ability of the present compounds in inhibiting the binding of 3 H-Prazosin to α 1 adrenoceptors in membranes from rat brain were determined in vitro according to Hyttel, J et al, J. Neurochem, 1985, 44, 1615; Skarsfeldt, T. et al, Eur. J. Pharmacol. 1986, 125, 323. Additionally the compounds of the invention were tested with respect to dopamine D 2 receptor binding activity according to van der Welde et al, Eur. J. Pharmacol. 1987, 134 , 211. For most compounds, the affinities for α 1 adrenoceptors and D 2 receptors were weak as compared to the potent binding to sigma receptors. Thus many of the compounds are very selective sigma receptor ligands, having ratios of binding affinities (IC 50 alpha/IC 50 sigma and IC 50 dopamine/IC 50 sigma, respectively) of 30-10000. LIGHT/DARK DISCRIMINATION TEST IN RATS. The test was carried out in accodance with F.C.Colpaert et al., Psychopharmacology (1985) 86: 45-54. The test used Wistar WU rats. The test was conducted using a two compartment activity box in which the actions of anxiolytic compounds to reduce aversion against a brightly-lit environment may be readily detected. The box is designed as an open-top experimental box one third of which was partitioned from the rest, painted black and illuminated with red light. The remainder of the box was painted white and brightly illuminated. The floor of each area was lined into squares. Behavioural changes were recorded. Data obtained from dose groups were analysed using single factor analysis of variance, and Dunnett's t-test. Test compounds were given intraperitoneally 45 min before testing. Several compounds have been tested in this test model and showed significant anxiolytic activities with ED 50 values in the ng-µg/kg dose range. FORMULATION EXAMPLES The pharmaceutical formulations of the invention may be prepared by conventional methods in the art. For example: Tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tabletting machine. Examples of adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatine, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colourings, flavourings, preservatives etc. may be used provided that they are compatible with the active ingredients. Solutions for injections may be prepared by dissolving the active ingredient and possible additives in a part of the solvent for injection, preferably sterile water, adjusting the solution to desired volume, sterilization of the solution and filling in suitable ampules or vials. Any suitable additive conventionally used in the art may be added, such as tonicity agents, preservatives, antioxidants, etc. Typical examples of recipes for the formulation of the invention are as follows: 1) Tablets containing 0.5 milligrams of Compound 1 a calculated as the freese: Comp. 1a 0.5 mg Lactose 18 mg Potato starch 27 mg Sucrose 58 mg Sorbitol 3 mg Talcum 5 mg Gelatine 2 mg Povidone 1 mg Magnesium stearate 0.5 mg 2) Tablets containing 5 milligrams of Compound 3b calculated as the free base: Comp. 3b 5 mg Lactose 16 mg Potato starch 45 mg Sucrose 106 mg Sorbitol 6 mg Talcum 9 mg Gelatine 4 mg Povidone 3 mg Magnesium stearate 0.6 mg 3) Syrup containing per milliliter: Comp. 6a 2.5 mg Sorbitol 500 mg Tragacanth 7 mg Glycerol 50 mg Methyl-paraben 1 mg Propyl-paraben 0.1 mg Ethanol 0.005 ml Water ad 1 ml 4) Solution for injection containing per milliliter: Comp. 7 1 mg Acetic acid 17.9 mg Sterile water ad 1 ml 5) Solution for injection containing per milliliter: Comp. 11 0.1 mg Sorbitol 42.9 mg Acetic acid 0.63 mg Sodium hydroxide 22 mg Sterile water ad 1 ml

Claims: Use of a piperidine compound having the general Formula I wherein X is CHR 10 , O, S, SO, SO 2 or NR 10 , R 10 being hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 8 cycloalkyl, adamantyl or C 3 -C 8 cycloalkyl(C 1 -C 20 )alkyl, C 3 -C 8 cycloalkenyl or C 3 -C 8 cycloalkenyl(C 1 -C 20 )alkyl, acyl, amino(C 1 -C 20 )alkyl, mono- or di(C 1 -C 20 )alkylamino(C1-C20)alkyl, sulfonyl or aryl(C 1 -C 20 )alkyl or phenyl optionally substituted with one or more substituents independently selected from the following: halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, trifluoromethyl, and cyano, or R 10 is 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-thiazolyl, 2-oxazolyl, 2-imidazolyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl; one or two of the dotted lines may be a bond; when the dotted line emanating from Y indicates a bond, Y is N or CH; or when said dotted line indicates no bond, Y is CH 2 , NH, C=O or C=S; R a - R d are independently selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulphonyl, C 1 -C 6 alkyl- or di(C 1 -C 6 )alkylamino, cyano, trifluoromethyl, or trifluoromethylthio; U is CH 2 , O or S; or when, one of the dotted lines emanating from U indicates a bond, U is CH; Q 2 is alkylene or alkenylene and Q 2 having from 2 to 20 carbon atoms; and R 2 and R 3 are independently hydrogen, C 1 -C 6 alkyl or they may be linked together thereby forming an ethylene or propylene bridge; R 4 to R 7 are independently selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, C 1 -C 6 alkylthio, C 1 -C 6 alkyl- or di(C 1 -C 6 )alkylamino, cyano, trifluoromethyl, or trifluoromethylthio; and Z 1 is a group as defined for R 4 - R 7 ; or an acid addition salt thereof for the manufacture of a pharmaceutical preparation for the treatment of anxiety, psychosis, epilepsy, convulsion, amnesia, cerebrovascular diseases, senile dementia of the Alzheimer type or Parkinson's disease. Use according to Claim 1, characterized in, that the compound of the general Formula I used is selected from the following: 1-(4-Fluorophenyl)-3-[4-(4-(4-fluorophenyl)-1-piperidyl)-1-butyl]indole; and 4-Fluorophenyl-3-[4-(4-(4-fluorophenyl)-1-piperidinyl)-1-butyl]-5-trifluoromethyl-indazol. A piperidine compound, characterized in, that it has the general Formula I wherein X is CHR 10 , O, S, SO, SO 2 or NR 10 , R 10 being hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 3 -C 8 cycloalkyl, adamantyl or C 3 -C 8 cycloalkyl(C 1 -C 20 )alkyl, C 3 -C 8 cycloalkenyl or C 3 -C 8 cycloalkenyl(C 1 -C 20 )alkyl, acyl, amino(C 1 -C 20 )alkyl, mono- or di(C 1 -C 20 )alkylamino(C 1 -C 20 )alkyl, sulfonyl or aryl(C 1 -C 20 )alkyl or phenyl optionally substituted with one or more substituents independently selected from the following: halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, trifluoromethyl, and cyano, or R 10 is 2-thienyl, 3-thienyl, 2-furanyl, 3-furanyl, 2-thiazolyl, 2-oxazolyl, 2-imidazolyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl; one or two of the dotted lines may be a bond; when the dotted line emanating from Y indicates a bond, Y is N or CH; or when said dotted line indicates no bond, Y is CH 2 , NH, C=O or C=S; R a - R d are independently selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, C 1 -C 6 alkylthio, C 1 -C 6 alkylsulphonyl, C 1 -C 6 alkyl- or di(C 1 -C 6 )alkylamino, cyano, trifluoromethyl, or trifluoromethylthio; U is CH 2 . O or S; or when, one of the dotted lines emanating from U indicates a bond, U is CH; Q 2 is alkylene or alkenylene and Q 2 having from 2 to 20 carbon atoms; and R 2 and R 3 are independently hydrogen, C 1 -C 6 alkyl or they may be linked together thereby forming an ethylene or propylene bridge; R 4 to R 7 are independently selected from hydrogen, halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, C 1 -C 6 alkylthio, C 1 -C 6 alkyl- or di(C 1 -C 6 )alkylamino, cyano, trifluoromethyl, or trifluoromethylthio; and Z 1 is a group as defined for R 4 - R 7 , with the proviso that if X is NR 10 where R 10 is hydrogen, alkyl or unsubstituted phenyl, Y is CH and the dotted line emanating from Y indicates a bond, then -U-Q 2 -may not be alkyl having less than 5 carbon atoms; and an acid addition salt thereof. A piperidine compound characterized in, that it is selected from the following: 1-(4-Fluorophenyl)-3-[4-(4-(4-fluorophenyl)-1-piperidyl)-1-butyl]indole; and 4-Fluorophenyl-3-[4-(4-(4-fluorophenyl)-1-piperidinyl)-1-butyl]-5-trifluoromethyl-indazol. A pharmaceutical composition, characterized in, that it comprises at least one novel piperidine compound according to Claim 3 or a pharmaceutically acceptable acid addition salt thereof in combination with one or more pharmaceutically acceptable carriers or diluents.

Inventors: MOLTZEN EJNER K, PERREGAARD JENS KRISTIAN, MOLTZEN, EJNER K., PERREGAARD, JENS KRISTIAN
Applicants: LUNDBECK & CO AS H, H. LUNDBECK A/S
Application year: 1992
Main classification: C07D491
IPC codes: C07D413, C07D491, C07D417, C07D401, C07D221, C07D495